Druggable Oncogene Fusions Found in KRAS Wild-Type Lung Invasive Mucinous Adenocarcinoma

Get Permission

As reported in Clinical Cancer Research, Nakaoku and colleagues identified oncogene fusions that function as driver mutations in KRAS wild-type invasive mucinous adenocarcinoma of the lung.

Whole-transcriptome sequencing of 32 invasive mucinous adenocarcinomas, including 27 without KRAS mutations, identified several oncogenic fusions that occurred only in the absence of KRAS mutations, including CD74-NRG1, EZR-ERBB4, and TRIM24-BRAF fusions. NRG1 fusions were present in 18% of KRAS-negative adenocarcinomas.

Functional analyses of the fusion gene products showed that the CD74-NRG1 fusion activated HER2:HER3 signaling and that EZR-ERBB4 and TRIM24-BRAF fusions constitutively activated the ERBB4 and BRAF kinases, respectively. Signaling pathway activation and fusion-induced anchorage-independent growth and tumorigenicity of NIH3T3 cells expressing these fusions were reduced by treatment with tyrosine kinase inhibitors.

The investigators concluded, “Oncogenic fusions act as driver mutations in [invasive mucinous adenocarcinomas] without KRAS mutations, and thus represent promising therapeutic targets for the treatment of such [disease].” ■

Nakaoku T, et al: Clin Cancer Res. April 11, 2014 (early release online).




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.